Durable Benefit Observed at 4 Years With Nivolumab Plus Ipilimumab in Advanced RCC
September 19th 2020At 4 years of follow-up, nivolumab and ipilimumab in combination as first-line therapy of advanced renal cell carcinoma demonstrated durable benefit versus sunitinib, according to research presented at the 2020 ESMO Virtual Congress.
Read More
Lanreotide Autogel Dosed More Frequently Delays More Toxic Regimens in Pancreatic, Midgut NETs
September 19th 2020For patients with progressive pancreatic or midgut neuroendocrine tumors, improvements in disease-free survival and progression-free survival were seen when the dosing of lanreotide Autogel was increased from 120 mg every 28 days to every 14 days. Data from the phase 2 CLARINET FORTE study suggest that this treatment option can delay switching to a more toxic treatment, which was presented at the 2020 ESMO Virtual Congress.
Read More
RO7122290 Active in First-in-Human Trial for Patients With Select Solid Tumors
September 19th 2020A first-in-human study of the bispecific antibody RO7122290 alone or in combination with atezolizumab showed preliminary antitumor activity and a good safety profile for patients with advanced solid tumors, according to findings of the trial presented at the ESMO Virtual Congress 2020.
Read More
Activity Observed With Balstilimab With or Without Zalifrelimab for Cervical Cancer
September 19th 2020In patients with recurrent/metastatic cervical cancer, the PD-1 inhibitor balstilimab monotherapy or combined with the CTLA-4 inhibitor zalifrelimab demonstrated promising objective response rates no matter the patients PD-L1 status, plus a tolerable safety profile, according to data from 2 independent phase 2 trials presented during the 2020 ESMO Virtual Congress.
Read More
NeoTRIPaPDL1 Trial Showed TIL Activity With Guidance From PD-L1 Status
September 19th 2020The combination of atezolizumab, carboplatin, and nab-paclitaxel increased pathological complete response by 10% or more in “immune-rich” patients with high-risk and locally advanced triple-negative breast cancer, as well as turned PD-L1 negative tumors positive most patients treated with immunotherapy, according to the phase 3 NeoTRIPaPDL1 trial data presented at the 2020 ESMO Virtual Congress.
Read More
Xevinapant Combination Induced Significant Overall Survival Improvements in LA-SCCHN
September 19th 2020The addition og xevinapant to standard cisplatin-based concomitant fractionation chemoradiation therapy led to a reduction in the risk of mortality as treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Read More
Frontline Nivolumab Plus Cabozantinib Significantly Improves Survival in Renal Cell Carcinoma
September 19th 2020Frontline nivolumab in combination with cabozantinib demonstrated a 49% reduction in the risk of disease progression or death as treatment of patients with advanced renal cell carcinoma.
Read More
Tumor Regression Is Observed With Neoadjuvant Atezolizumab in Resectable NSCLC
September 19th 2020In patients with non–small cell lung cancer who were eligible for surgical resection, treatment with one dose of neoadjuvant atezolizumab was considered safe and induced major pathological responses in some patients.
Read More
Pembrolizumab/Lenvatinib Combo Achieves Promising Responses in Anaplastic Thyroid Cancer
September 19th 2020Christine Dierks, MD, discusses the results from the prospective phase 2 ATLEP study of lenvatinib in combination with pembrolizumab as treatment of patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.
Read More
Survival Improved With Frontline Avelumab as Maintenance in Advanced Urothelial Carcinoma
September 19th 2020Avelumab in combination with best supportive care as frontline maintenance in patients with advanced or metastatic urothelial carcinoma who had not progressed on first-line platinum-based chemotherapy led to improvements in both progression-free and overall survival.
Read More
Durable Responses Observed With PD-1/PD-L1 Combination in Urothelial Carcinoma
September 19th 2020The addition of BGB-A333 to tislelizumab led to marked antitumor activity and durable responses with a tolerable safety profile as treatment of patients with urothelial carcinoma in the phase 1/2 BGB-900-101 study.
Read More
Ipatasertib Combination Misses End Points in HR+ HER2- Advanced Breast Cancer
September 19th 2020An improvement in progression-free survival and objective response rate was not observed with the addition of ipatasertib to paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive, HER2-negative advanced breast cancer.
Read More
Futibatinib Induces Durable Responses in FGFR2+ Intrahepatic Cholangiocarcinoma
September 18th 2020Futibatinib demonstrated efficacy and tolerability when administered as treatment of patients with intrahepatic cholangiocarcinoma who harbor FGFR2 fusions/rearrangements, according to interim analysis results presented in a poster during the the European Society of Medical Oncology Virtual Congress 2020
Read More
Durability of Responses With Larotrectinib Demonstrated in TRK+ Lung Cancer Population
September 17th 2020Larotrectinib induced durable responses in patients with TRK fusion–positive lung cancer, even in patients with central nervous system metastases, according to results pooled from 2 trials of the TRK inhibitor and presented in a poster at the European Society of Medical Oncology Virtual Congress 2020.
Read More
Clinically Meaningful Improvement in TRK Fusion Cancer Detected with Larotrectinib
October 3rd 2019Using a measure known as the growth modulation index, patients with TRK fusion–positive cancers who were treated with larotrectinib had a clinically meaningful improvement in progression-free survival compared with the time to progression on their prior treatment, an analysis of patients enrolled in 1 of 3 clinical trials has found.
Read More
Nivolumab Plus Ipilimumab Shows Durable Clinical Activity in Cervical Cancer
October 1st 2019In the CheckMate-358 study, the combination of nivolumab and ipilimumab showed durable clinical activity in patients with recurrent or metastatic cervical cancer, regardless of tumor PD-L1 expression.
Read More
Nivolumab Improves OS in Advanced Esophageal Cancer
October 1st 2019In the phase III ATTRACTION-3 study, nivolumab prolonged overall survival compared with chemotherapy in patients with previously treated advanced esophageal squamous cell carcinoma, according to findings presented at the 2019 ESMO Congress.
Read More
Pembrolizumab Does Not Improve PFS Over Chemotherapy in Relapsed Malignant Pleural Mesothelioma
September 30th 2019Progression-free survival was not improved with pembrolizumab over chemotherapy in patients with malignant pleural mesothelioma, missing the primary endpoint of the phase III European Thoracic Oncology Platform PROMISE-meso trial presented at the 2019 ESMO Congress.
Read More
Risk of Progression or Death Reduced With Ivosidenib in Advanced Cholangiocarcinoma
September 30th 2019The risk of progression or death was reduced by 63% with ivosidenib as treatment of pretreated patients with IDH1-mutant advanced cholangiocarcinoma compared with placebo, according to data from the phase III ClarIDHy study that was presented at the 2019 ESMO Congress.
Read More
Abemaciclib Leads to Positive Benefit in Chinese Women With HR+ Breast Cancer
September 30th 2019CDK4/6 inhibitor abemaciclib plus endocrine therapy led to significant benefits in a population of predominantly Chinese women with advanced hormone receptor–positive/HER2-negative breast cancer, according to data from 2 randomized trials presented at the 2019 ESMO Congress.
Read More
First-Line Atezolizumab/Chemotherapy Improves Outcomes in Metastatic Urothelial Cancer
September 30th 2019In patients with locally advanced or metastatic urothelial carcinoma, atezolizumab and chemotherapy improved median progression-free survival by 1.9 months compared with placebo and chemotherapy. However, no overall survival benefit was seen, according to results of the phase III IMvigor130 trial presented at the 2019 ESMO Congress.
Read More
Olaparib Improves rPFS in Heavily Pretreated HRR+ mCRPC
September 30th 2019In the phase III PROfound trial, olaparib improved radiographic progression-free survival compared to either abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer, who had homologous recombination repair gene alterations, according to findings presented at the 2019 ESMO Congress.
Read More
Selpercatinib Demonstrates Robust ORR in Thyroid Cancer
September 29th 2019Strong objective responses rates were seen in the phase I/II LIBRETTO trial, which studied RET inhibition with selpercatinib in patients with <em>RET</em>-mutant medullary thyroid cancer and for those with other <em>RET</em> fusion-positive thyroid cancer. The registrational findings were recently presented at ESMO Congress 2019.
Read More
Larotrectinib Maintains Safety and High Efficacy in TRK Fusion-Positive Cancer
September 29th 2019Three clinical trials presented at the 2019 ESMO Congress show that the tropomyosin receptor kinase inhibitor larotrectinib continues to show anti-tumor activity, including long-lasting objective responses and low toxicity, according to results from an integrated analysis.
Read More
Abemaciclib/Fulvestrant Demonstrates Overall Survival Benefit in HR+ Advanced Breast Cancer
September 29th 2019Results from the phase III MONARCH 2 trial showed that the addition of the CDK4/6 inhibitor abemaciclib to fulvestrant improved overall survival by 9.4 months compared with fulvestrant and placebo in patients with hormone receptor–positive, HER2-negative advanced breast cancer who progressed on prior endocrine therapy, according to data presented at the 2019 ESMO Congress.
Read More
Subpar Concordance Seen With PD-L1 Assays in Advanced TNBC
September 29th 2019A subgroup of patients with triple-negative breast cancer who had immune cell PD-L1 expression, by the SP142 immunohistochemistry assay had responses to atezolizumab and nab-paclitaxel, regardless of whether they had primary or metastatic disease, according to an exploratory biomarker substudy of IMpassion130.
Read More